Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells (US5773479)

Application Number	Filed	Patent	Pub. Date	Title
US1994000300357	1994-09-02		1995-12-05	Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US1993000061714	1993-05-13


	Parent Case:			This application is a division of U.S. patent application Ser. No. 08/300,357, filed Sept. 2, 1994, now U.S. Pat. No. 5,472,985, which application, in turn, is a continuation of U.S. patent application Ser. No. 08/061,714, filed May 13, 1993, now abandoned.
	Designated Country:			AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE CA EP JP
	Family:			Show 68 known family members
	First Claim: Show all 5 claims			What is claimed is: 1. A method to treat atherosclerosis comprising the systemic administration to a mammal of an amount of trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine or an analog thereof that is effective to inhibit or reduce lesion formation or development in, or lipid accumulation by, a vessel of said mammal.
	Background / Summary:			Show background / summary
	Drawing Descriptions:			Show drawing descriptions
	Description:			Show description
	Forward References:			Show 17 U.S. patent(s) that reference this one

U.S. References:

Go to Result Set: All U.S. references | Forward references (17) | Backward references (59) | Citation Link

Patent	Pub.Date	Inventor	Assignee	Title
US2914563	1959-11	Allen et al.		Therapeutic composition
US3010965	1961-11	Elpern		1, 1, 2-tris-aryl-3-tertiary-amino-1-propenes, intermediates, and preparation thereof
US3634517	1972-01	Palopoli et al.		TRIARYLALKENONES
US4133814	1979-01	Jones et al.	Eli Lilly and Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862	1980-10	Suarez et al.	Eli Lilly and Company	Antifertility compounds
US4235988	1980-11	Fildes et al.	Imperial Chemical Industries Limited	Delivery means for biologically active agents
US4307111	1981-12	Crawley	Imperial Chemical Industries Limited	1-Hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives
US4418068	1983-11	Jones	Eli Lilly and Company	Antiestrogenic and antiandrugenic benzothiophenes
US4442119	1984-04	Magarian et al.	The Board of Regents for the University of Oklahoma	Cyclopropyl analogs as estrogenic and anti-fertility agents
US4536516	1985-08	Harper et al.	Imperial Chemical Industries PLC	Alkene derivatives
US4696949	1987-09	Toivola et al.	Farmos Group Ltd.	Novel tri-phenyl alkane and alkene derivatives and their preparation and use
US4824436	1989-04	Wolinsky		Method for the prevention of restenosis
US4826672	1989-05	Milius et al.	President and Fellows of Harvard College	Astatinated organic compounds
US4839155	1989-06	Mccague	National Research Development Corporation	Iodotamoxifen derivatives and use for estrogen receptor-positive breast cancer detection and therapy
US4859585	1989-08	Sonnenschein et al.	Trustees of Tufts College	In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4879315	1989-11	Magarian et al.	The Board of Regents for the University of Oklahoma	Cyclopropyl analogs as anti-estrogenic, anti-tumor and female fertility agents
US4962091	1990-10	Eppstein et al.	Syntex (U.S.A.) Inc.	Controlled release of macromolecular polypeptides
US4973755	1990-11	Grafe et al.	Heumann Pharma GmbH & Co.	Stable solvent adducts of Z-1-(p-β-dimethylaminoethoxy-phenyl)-1-(p-hydroxyphenyl)-2-phenyl-but-1-ene
US4990538	1991-02	Harris et al.		Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US4996225	1991-02	Toivola et al.	Farmos Group Ltd.	Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses
US4997652	1991-03	Wong	Visionex	Biodegradable ocular implants
US5015666	1991-05	Magarian et al.	Board of Reagents of the University of Oklahoma	Triarylcyclopropanes as antiestrogens and antitumor agents
US5032679	1991-07	Brandley et al.	Glycomed, Inc.	Heparin fragments as inhibitors of smooth muscle cell proliferation
US5047431	1991-09	Schickaneder et al.	Klinge Pharma GmbH & Co.	1,1,2-triphenylbut-1-ene derivatives
US5098903	1992-03	Magarian et al.	Board of Regents of the University of Oklahoma	Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
US5112305	1992-05	Barath et al.	Cedars-Sinai Medical Center	Catheter device for intramural delivery of therapeutic agents
US5120535	1992-06	Marquardt et al.	Oncogen	Oncostatin M and novel compositions having anti-neoplastic activity
US5140012	1992-08	McGovern et al.	E. R. Squibb & Sons, Inc.	Method for preventing onset of restenosis after angioplasty employing pravastatin
US5166143	1992-11	Ondetti et al.	E. R. Squibb & Sons, Inc.	Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
US5171217	1992-12	March et al.	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
US5189046	1993-02	Burch et al.	Nova Pharmaceutical Corporation	Protein kinase C modulators
US5189212	1993-02	Ruenitz	University of Georgia Research Foundation, Inc.	Triarylethylene carboxylic acids with estrogenic activity
US5192525	1993-03	Yang et al.	Board of Regents, The University of Texas System	High affinity tamoxifen derivatives and uses thereof
US5208019	1993-05	Hanson et al.		Use of gamma-interferon for the treatment of vascular stenosis
US5216024	1993-06	Markaverich et al.	Baylor College of Medicine	Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5219548	1993-06	Yang et al.	Board of Regents, The University of Texas System	High affinity halogenated-tamoxifen derivatives and uses thereof
US5221620	1993-06	Purchio et al.	Oncogen	Cloning and expression of transforming growth factor β2
US5238950	1993-08	Clader et al.	Schering Corporation	Inhibitors of platelet-derived growth factor
US5254594	1993-10	Niikura et al.	Klinge Pharma GmbH	Remedies for bone diseases
US5268358	1993-12	Fretto	Cor Therapeutics, Inc.	PDGF receptor blocking peptides
US5270047	1993-12	Kauffman et al.		Local delivery of dipyridamole for the treatment of proliferative diseases
US5280016	1994-01	Conrad et al.	Glycomed Incorporated	Non-anticoagulant heparin derivatives
US5280109	1994-01	Miyazono et al.	Ludwig Institute for Cancer Research	Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
US5283257	1994-02	Gregory et al.	The Board of Trustees of the Leland Stanford Junior University	Method of treating hyperproliferative vascular disease
US5284763	1994-02	Derynk et al.	Genentech, Inc.	Nucleic acid encoding TGF-β and its uses
US5288711	1994-02	Mitchell et al.	American Home Products Corporation	Method of treating hyperproliferative vascular disease
US5304541	1994-04	Purchio et al.	Bristol-Myers Squibb Company	Methods using novel chimeric transforming growth factor-β1/β2
US5308622	1994-05	Casscells et al.	The Salk Institute for Biological Studies	Treatment of vascular injury
US5308862	1994-05	Ohlstein	Boehringer Mannheim Pharmaceuticals Corporation - SmithKline Beecham Corp., Ltd. Partnership No. 1	Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5324736	1994-06	Magarin et al.	Research Corporation Technologies, Inc.	Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
US5326757	1994-07	Demopoulos	Health Maintenance Programs, Inc.	Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
US5362424	1994-11	Lee et al.	Korea Research Institute of Chemical Technology	Microencapsulation for controlled oral drug delivery system
US5393763	1995-02	Black et al.	Eli Lilly and Company	Methods for inhibiting bone loss
US5393785	1995-02	Labrie et al.	Endorecherche, Inc.	Therapeutic antiestrogens
US5395842	1995-03	Labrie et al.	Endorecherche Inc.	Anti-estrogenic compounds and compositions
US5453436	1995-09	Ohlstein	Boehringer Mannheim Pharmaceutical Corporation	Treatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine compounds
US5468746	1995-11	Casagrande et al.	Zambon Group S.p.A.	Compounds active on the cardiovascular system
US5482949	1996-01	Black et al.	Eli Lilly and Company	Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5491173	1996-02	Toivola et al.	Orion-yhtyma Oy	Tri-phenyl alkene derivatives and their preparation and use

Foreign References:

Publication	Date	IPC Code	Assignee	Title
EP0095875	1983-07	A61K 31/045	Farmos Group Ltd.	Novel tri-phenyl alkane and alkene derivatives and their preparation and use
EP0260066B1	1988-03	A61K 51/00	NATIONAL RESEARCH DEVELOPMENT CORPORATION	Tamoxifen derivatives
GB1105787	1962-01
WO8500107	1985-01	A61K 31/13	KERB, Ulrich	PROPHYLAXIS AND THERAPY OF CORONARY HEART DISEASES BY LOWERING THE ESTROGEN CONCENTRATION
WO0374044	1990-06
WO9115222	1991-10	A61K 37/02	GENENTECH INC	METHOD OF PREDISPOSING MAMMALS TO ACCELERATED TISSUE REPAIR
WO9206068	1992-04	A61K 31/135	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	HIGH AFFINITY TAMOXIFEN DERIVATIVES AND USES THEREOF
WO9208480	1992-05	A61K 37/36	CELTRIX LABORATORIES, INC.	A 'beta'-TYPE TRANSFORMING GROWTH FACTOR
WO9218546	1992-10	C07H 11/00	BRANDLEY, Brian, K.	SULFATED POLYSACCHARIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION